stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Return on invested capital
GeneDx Holdings Corp.'s return on invested capital over the twelve months to 30 June 2026 was −27.7%, down 23.3 percentage points from fiscal 2025 (−4.42%). Over the past ten years it has ranged from −306.8% (fiscal 2022) to 0.00% (fiscal 2021); the current reading is higher than 57% of that period. That is below the Diagnostics & Research industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −4.42% | 4.88 |
| FY2024 | −9.30% | 65.67 |
| FY2023 | −75.0% | 231.81 |
| FY2022 | −306.8% | (306.78) |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CDNA CareDx, Inc. compare | 33.6% |
| VCYT Veracyte, Inc. compare | 4.33% |
| ADPT Adaptive Biotechnologies Corporation compare | 0.00% |
| FRNM Freenome, Inc compare | 0.00% |
| NEO NeoGenomics, Inc. compare | −2.97% |
| CSTL Castle Biosciences, Inc. compare | −3.63% |
| OPK OPKO Health, Inc. compare | −6.72% |
| WGS GeneDx Holdings Corp. | −27.7% |
| PSNL Personalis, Inc. compare | −358.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement